Type 1 interferons as a potential treatment against COVID-19
École Normale Supérieure - PSL · Hôpital Bichat-Claude-Bernard · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
552
total citations
- FWCI
- 13.54
- Percentile
- 100%
- References
- 50
Citations per year
Authors
5- ESErwan Sallard
École Normale Supérieure - PSL
- FLFrançois-Xavier Lescure
Hôpital Bichat-Claude-Bernard, Assistance Publique – Hôpitaux de Paris, Université Claude Bernard Lyon 1, Université Paris Cité, Inserm
- YYYazdan Yazdanpanah
Hôpital Bichat-Claude-Bernard, Assistance Publique – Hôpitaux de Paris, Université Claude Bernard Lyon 1, Université Paris Cité, Inserm
- FMFrance Mentré
Université Paris Cité, Inserm
- NPNathan Peiffer‐SmadjaCorresponding
Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard, Inserm, Université Claude Bernard Lyon 1, Université Paris Cité
Topics & keywords
Topics
Keywords
- Coronavirus disease 2019 (COVID-19)
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Clinical trial
- 2019-20 coronavirus outbreak
- Medicine
- Clinical significance
- Virology
- Betacoronavirus
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.